Recombinant Acinetobacter baumannii NDM-1 Protein ，His & SUMO

NDM-1 (New Delhi Metallo-beta-lactamase-1) is a significant beta-lactamase enzyme first identified in bacteria isolated from patients in New Delhi, India, in 2008. This enzyme is notorious for conferring resistance to a broad range of beta-lactam antibiotics, including carbapenems, which are often regarded as antibiotics of last resort for treating multidrug-resistant bacterial infections. The rise of NDM-1-producing bacteria poses a severe public health threat globally, leading to treatment failures and increased morbidity and mortality rates. Research on NDM-1 recombinant proteins has focused on understanding the enzyme's structure and function to develop effective inhibitors and alternative therapeutic strategies. Studies have focused on the characterization of the enzyme's active site, substrate specificity, and the molecular mechanisms underlying its resistance properties. By engineering recombinant NDM-1 proteins, researchers aim to elucidate the biochemical pathways of antibiotic resistance and screen potential inhibitors that could restore the efficacy of existing antibiotics. Furthermore, this research contributes to the design of novel antimicrobial agents and informs public health strategies to combat the spread of antibiotic-resistant infections. As NDM-1 continues to emerge in various pathogens worldwide, ongoing studies of its recombinant form are crucial for developing a proactive approach to managing antibiotic resistance.